Navigation Links
Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
Date:2/22/2010

t to risks and uncertainties.  Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE and requisite receipt of FDA licensure for marketing.  Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

    
                               DENDREON CORPORATION                       
                       CONSOLIDATED STATEMENTS OF OPERATIONS                  
                     (in thousands, except per share amounts)                 
                                                                              
                                     Three months ended    Twelve months ended
                                        December 31,           December 31, 
                                     ------------------    -------------------
                                     2009           2008      2009      2008 
                                     ----           ----      ----      ---- 
                                         (unaudited)       
'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
2. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
3. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
4. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
5. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
6. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
7. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
8. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
11. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 12, 2014 Research and Markets ( ... "Inferior Vena Cava (IVC) Filters - Global Trends, Estimates ... http://photos.prnewswire.com/prnh/20130307/600769 Global ... reach US$435 million by 2016. The North ... the global value while Europe ...
(Date:12/15/2014)... , December 15, 2014 BerGenBio ... for aggressive drug resistant cancers, today announces that it ... private placing from new and existing investors. ... support the development of its pipeline of innovative cancer ... its lead drug candidate, BGB324, a first-in-class selective Axl ...
(Date:12/15/2014)... PLYMOUTH MEETING, Pa. , Dec. 15, 2014 ... ) announced today it has been added to ... the NASDAQ Biotechnology Index will become effective upon ... The NASDAQ Biotechnology Index is designed to track ... that are classified as either biotechnology or pharmaceutical ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
(Date:12/17/2014)... Unidesk Corporation today announced that ... welcomed its inaugural class in August 2013, has ... support bring your own device (BYOD) and deliver ... The solution, comprised of Citrix XenDesktop ... and storage infrastructure and Unidesk virtual ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
(Date:12/17/2014)... (HealthDay News) -- Expectant parents should leave prenatal picture-taking ... recommends. Use of ultrasound imaging and heartbeat monitors ... risk-free, the agency warns. "Although there is ... ultrasound imaging and heartbeat monitors, prudent use of these ... Vaezy, an FDA biomedical engineer, said in an agency ...
(Date:12/17/2014)... Kathleen Doheny HealthDay ... Chronic sleep loss is rampant in America, and work commitment ... is the No. 1 sleep killer," said Dr. Mathias Basner, ... the University of Pennsylvania Perelman School of Medicine. A ... older, found that work is the main activity exchanged for ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
Breaking Medicine News(10 mins):Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3
... HealthDay Reporter , TUESDAY, June 28 (HealthDay News) -- ... U.S. regulators, attention again Tuesday during a two-day hearing to ... the treatment of metastatic breast cancer. Back on Dec. ... of the drug to fight breast cancer, citing the ...
... University School of Medicine in St. Louis are performing ... irregular heartbeat. Available at only a handful of ... surgical techniques with the latest advances in catheter ablation, ... surface to block signals causing the heart to misfire. ...
... care nurses doubt that a clinical neurological examination can establish ... perceive that this uncertainty can affect relatives when the question ... from the Sahlgrenska Academy, University of Gothenburg, Sweden. ... caring for patients who are brain dead and who by ...
... with social interaction and attentiveness, and are also sensitive ... evident to parents during their child,s first two years, ... of Gothenburg. In her thesis, Dewrang investigated ... relative to their diagnosis. The thesis is based on ...
... mutations for two classes of p7 inhibitor, which may ... with current standard of care. Study results support the ... future HCV-specific therapies and are available in the July ... Wiley-Blackwell on behalf of the American Association for the ...
... regulated, as mistakes may lead to cancer. The so-called c-JUN ... and liver. The group of Veronika Sexl at the ... detail with the discovery an additional function of c-JUN,s also ... have recently been published in the open-access journal Oncotarget ...
Cached Medicine News:Health News:FDA to Hear Appeal on Breast Cancer Drug 2Health News:FDA to Hear Appeal on Breast Cancer Drug 3Health News:New procedure treats atrial fibrillation 2Health News:New procedure treats atrial fibrillation 3Health News:New procedure treats atrial fibrillation 4Health News:Intensive care nurses have doubts about method for establishing brain death 2Health News:Intensive care nurses have doubts about method for establishing brain death 3Health News:P7 protein resistance mutations identified; represent drug targets for hepatitis C virus 2Health News:The good, the bad and the ugly: The many roles of c-JUN in cancer 2
... operation for stent delivery. Uses perpendicular ... movement. Allows user to adjust stent ... Maintains tactile feel via fine adjustment ... in visualization at any angle. The ...
Vial with 100 Urine Reagent Test Strips, tests for glucose, protein, pH, blood, ketone, bilirubin, nitrite, urobilinogen, specific gravity. FOR LABORATORY USE BY QUALIFIED TECHNICIANS....
... the latest from Quality Mapping Solutions, ... designed specifically for implementing and managing ... superior design, functionality, security, and versatility ... managing a quality program., ,Based upon ...
... Q-Pulse is the UK's market-leading system ... 250 pathology laboratories in the UK ... In addition, hundreds of pathology laboratories ... South Africa and the United States ...
Medicine Products: